NASDAQ:PTGX - Protagonist Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.09 -0.25 (-3.41 %)
(As of 06/20/2018 04:00 PM ET)
Previous Close$7.09
Today's Range$6.98 - $7.49
52-Week Range$5.50 - $23.97
Volume265,117 shs
Average Volume218,754 shs
Market Capitalization$153.73 million
P/E Ratio-3.39
Dividend YieldN/A
Beta3.28
Protagonist Therapeutics logoProtagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis. It is also developing an oral peptide targeting a GI condition other than IBD. The company was founded in 2006 and is headquartered in Newark, California.

Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTGX
CUSIPN/A
Phone510-474-0170

Debt

Debt-to-Equity RatioN/A
Current Ratio4.19
Quick Ratio4.19

Price-To-Earnings

Trailing P/E Ratio-3.39
Forward P/E Ratio-7.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.06 million
Price / Sales7.49
Cash FlowN/A
Price / CashN/A
Book Value$5.89 per share
Price / Book1.20

Profitability

EPS (Most Recent Fiscal Year)($2.09)
Net Income$-36,950,000.00
Net MarginsN/A
Return on Equity-34.47%
Return on Assets-24.72%

Miscellaneous

Employees55
Outstanding Shares21,200,000

Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics Inc (NASDAQ:PTGX) issued its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by $0.07. The business earned $10.78 million during the quarter, compared to analysts' expectations of $10.70 million. View Protagonist Therapeutics' Earnings History.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Protagonist Therapeutics.

What price target have analysts set for PTGX?

4 analysts have issued 12-month price objectives for Protagonist Therapeutics' stock. Their predictions range from $13.00 to $36.00. On average, they expect Protagonist Therapeutics' stock price to reach $24.75 in the next twelve months. View Analyst Ratings for Protagonist Therapeutics.

Who are some of Protagonist Therapeutics' key competitors?

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the folowing people:
  • Dr. Dinesh V. Patel, CEO, Pres, Sec. & Director (Age 61)
  • Dr. Richard S. Shames M.D., Chief Medical Officer (Age 58)
  • Dr. David Y. Liu Ph.D., Chief Scientific Officer and Head of R&D (Age 68)
  • Mr. Thomas P. O'Neil, CFO & Principal Accounting Officer (Age 53)
  • Dr. Mark Smythe Ph.D., VP of Technology & Alliances (Age 53)

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

Has Protagonist Therapeutics been receiving favorable news coverage?

Media stories about PTGX stock have been trending positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Protagonist Therapeutics earned a daily sentiment score of 0.34 on Accern's scale. They also assigned headlines about the company an impact score of 45.44 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Farallon Capital Management LLC (4.78%), BlackRock Inc. (3.24%), BVF Inc. IL (1.92%), Millennium Management LLC (1.51%), American Century Companies Inc. (0.67%) and Spark Investment Management LLC (0.39%). Company insiders that own Protagonist Therapeutics stock include Armen Shanafelt, Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Richard S Shames, Thomas P O'neil and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics.

Which institutional investors are buying Protagonist Therapeutics stock?

PTGX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Millennium Management LLC, Farallon Capital Management LLC, BVF Inc. IL, Spark Investment Management LLC, Citadel Advisors LLC and Federated Investors Inc. PA. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Armen Shanafelt and Bryan Giraudo. View Insider Buying and Selling for Protagonist Therapeutics.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $7.09.

How big of a company is Protagonist Therapeutics?

Protagonist Therapeutics has a market capitalization of $153.73 million and generates $20.06 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Protagonist Therapeutics employs 55 workers across the globe.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560-1160. The company can be reached via phone at 510-474-0170 or via email at [email protected]


MarketBeat Community Rating for Protagonist Therapeutics (PTGX)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  243
MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe PTGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.